WHO ICTRP trial
Observational study of pomalidomide alone and in combination in the treatment of…
ChiCTR2100053250 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100053250 |
|---|---|
| Public title | Observational study of pomalidomide alone and in combination in the treatment of PCNSL |
| Scientific title | An open-label, single-center observational study evaluating the efficacy and safety of pomalidomide monotherapy and combination therapy in patients with primary central nervous system lymphoma (PCNSL). |
| Primary sponsor | Lanzhou University Second Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 2 |
| Countries | China |
| Conditions | Primary central nervous system lymphoma |
| Interventions | Maintenance treatment group for high-risk patients:Pomalidomide monotherapy;Elderly (>=60 years old) patient group who were initially intolerant/unsuitable for HD-MTX:Pomalidomide combined with rituximab |
| Registration date | Nov 17, 2021 |
| Target size | Maintenance treatment group for high-risk patients:10;Elderly (>=60 years old)… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: